ReviewPathogens & immunity2022
Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans.
Review in Pathogens & immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Frontiers in microbiology · 2024Pooled it
- Bacteriophage-mediated reduction of Pseudomonas aeruginosa biofilm on titanium surfaces for biomedical applications.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Therapeutic efficacy of a K1-specific bacteriophage against hypervirulent Klebsiella pneumoniae in a mouse infection model.Virologica Sinica · 2026Article
- Assessment of Compliance with National and International Guidelines in the Empirical Management of Community-Acquired Pneumonia (CAP) in Lebanese Hospitals: A Multicenter Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2026Article
- Novel lytic phages improve the antibiofilm activity of dalbavancin, daptomycin, and fosfomycin against vancomycin-resistant enterococci.Microbiology spectrum · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Eating Away at Antibiotic Resistance - Is Phage Therapy Our Future?Pathogens & immunity · 2026Article
- A capsule-dependent lytic phage for targeting multidrug-resistant and hypervirulentApplied and environmental microbiology · 2025Article
- Characteristics and Outcomes of Patients Treated with Carbapenem Versus Non-carbapenem Therapy for AmpC-Producing Enterobacterales Bacteremia: A Retrospective Study.Infectious diseases and therapy · 2025Article
- Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention.Nature reviews. Microbiology · 2025Review
- Emerging antimicrobial therapies for Gram-negative infections in human clinical use.npj antimicrobials and resistance · 2025Review
- Bacteriophage treatment is effective against carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Complete genome sequences of threeMicrobiology resource announcements · 2024Article
- The Evolution of Phage Therapy: A Comprehensive Review of Current Applications and Future Innovations.Cureus · 2024Review
- Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024Review
- Article
- Mucin and Agitation Shape Predation ofMicroorganisms · 2023Article
- Modeling the Directed Evolution of Broad Host Range Phages.Antibiotics (Basel, Switzerland) · 2022Article
- The Effects of Ventilation, Humidity, and Temperature on Bacterial Growth and Bacterial Genera Distribution.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.